Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.
Multiple sclerosis (MS) is an autoimmune central nervous system (CNS) demyelinating disease that causes relapsing and chronic neurologic impairment. Recent observations have altered certain traditional concepts regarding MS pathogenesis. A greater diversity of cell types and molecules involved in MS is now evident. While remyelination can occur during the early inflammatory phase when damage may be reversible, it is impaired in the later stages, which involve axonal death. These observations have important therapeutic implications.
Zamvil
Scott S
SS
Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA. zamvil@ucsf.neuroimmunol.org
Steinman
Lawrence
L
D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D001369:Axons / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D016923:Cell Death / Q000276:immunology*; D004660:Encephalitis / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D009186:Myelin Sheath / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D009410:Nerve Degeneration / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology
D001323:Autoantibodies; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors